Oral Rehydration Therapy

Oral rehydration therapy (ORT) is a foundational clinical and public health intervention for preventing and treating fatal dehydration caused by acute secretory gastroenteritis—most notably cholera (Vibrio cholerae), enterotoxigenic Escherichia coli (ETEC), and rotavirus—through the oral administration of an equimolar solution of sodium chloride, glucose (or complex starch), potassium, and an alkalinizing base (citrate or bicarbonate) dissolved in clean water (Oral Rehydration Salts, ORS). Described in a famous 1978 Lancet editorial as "potentially the most important medical advance this century," oral rehydration therapy represents a direct triumph of fundamental membrane biophysics translated to global field medicine. Prior to the late 1960s, severe cholera—which can purge up to 1 liter of isotonic fluid per hour from the small intestine, killing 50% of untreated patients within 24 hours from hypovolemic shock and metabolic acidosis—could only be treated with sterile intravenous (IV) saline infusions, which were unavailable in rural clinics and refugee camps. The discovery by biochemists Robert K. Crane (1960), Stanley G. Schultz and Ralph A. Zalusky (1964) that the apical brush-border sodium–glucose cotransporter 1 (SGLT1) remains completely intact and functional during cholera toxin poisoning enabled physicians Norbert Hirschhorn, David R. Nalin, Richard A. Cash, Dilip Mahalanabis, and Nathaniel F. Pierce in Dhaka and Kolkata (1968–1971) to reduce intravenous fluid requirements by 80% and cut epidemic cholera mortality in field camps from ~30–50% down to <1%, saving an estimated 50 to 70 million children's lives worldwide over the past half-century (Crane, 1960; Nalin et al., 1968; Mahalanabis et al., 1973; Editorial, The Lancet, 1978; Binder et al., 2014).

Why does a cholera patient who drinks plain water or simple salt water (NaCl without glucose) simply vomit or pass the fluid straight out as profuse watery diarrhea, growing ever more dehydrated?

To understand the biophysical mechanism, one must distinguish the two spatially and biochemically separate transport systems operating simultaneously across the human small-intestinal mucosa (Field, 2003; Wright et al., 2011; Binder et al., 2014):

1. The Cholera Toxin Lesion in Intestinal Crypt Cells (cAMP-Driven Cl⁻ Secretion + Blocked Neutral NaCl Absorption):
   • When the Gram-negative bacterium Vibrio cholerae colonizes the small intestine, its AB₅ cholera enterotoxin (CT) binds ganglioside GM1 receptors on enterocytes and delivers its catalytic A1 subunit inside the cell. The A1 subunit ADP-ribosylates the α-subunit of the stimulatory G-protein (G_sα), locking adenylyl cyclase in a permanently active state and elevating intracellular cyclic AMP (cAMP) 100-fold.
   • High intracellular cAMP has two major effects on ion transport: (a) in secretory crypt cells, cAMP activates protein kinase A (PKA) to phosphorylate and open apical CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) chloride channels, pouring Cl⁻ ions into the intestinal lumen (which drag Na⁺ and H₂O paracellularly into the gut); and (b) in absorptive villus cells, high cAMP inhibits the neutral Na⁺/H⁺ exchanger (NHE3), shutting down the normal pathway by which plain NaCl is absorbed. Consequently, if a cholera patient drinks plain salt water, zero Na⁺ is absorbed via NHE3, and the ingested fluid adds directly to the secretory purge.
2. The Intact Escape Pathway on Villus Tip Cells: Sodium–Glucose Cotransporter 1 (SGLT1, SLC5A1):
   • In August 1960 at the Symposium on Membrane Transport and Metabolism in Prague, American biochemist Robert K. Crane formulated the flux-coupling (secondary active cotransport) hypothesis: intestinal absorption of glucose against its concentration gradient is directly coupled to the downhill inward movement of Na⁺ ions across a single brush-border carrier protein—now known as SGLT1 (cloned by Ernest M. Wright and colleagues in 1987, encoded by SLC5A1 on chromosome 22q12.3).
   • Using short-circuited rabbit ileum Ussing chambers, Stanley G. Schultz and Ralph A. Zalusky (1964) proved that adding glucose to the mucosal bath immediately stimulates a stoichiometric inward Na⁺ current—and crucially, SGLT1 on villus tip cells is insensitive to intracellular cAMP, cGMP, or Ca²⁺ levels. Even when cholera toxin maximally activates CFTR chloride secretion in the crypts and blocks NHE3, SGLT1 continues to pump Na⁺ and glucose into the villus enterocytes at full capacity.

The Stoichiometric SGLT1 Transport Cycle (2 Na⁺ : 1 Glucose : ~210–260 H₂O)

Across the enterocyte plasma membrane, SGLT1 operates as an electrogenic secondary active symporter driven by the basolateral Na⁺/K⁺-ATPase pump (Wright et al., 2011):

1. Basolateral Na⁺ Extrusion: The basolateral Na⁺/K⁺-ATPase hydrolyzes ATP to pump 3 Na⁺ out of the enterocyte into the interstitial blood space in exchange for 2 K⁺ in, maintaining a low intracellular sodium concentration ([Na⁺]_in ≈ 15 mM vs. lumen [Na⁺]_out ≈ 75–90 mM) and a negative intracellular membrane potential (−40 to −50 mV).
2. Apical SGLT1 Symport (2 Na⁺ : 1 Glucose): On the apical microvillar brush border, each turnover of SGLT1 binds two luminal Na⁺ ions and one D-glucose (or D-galactose) molecule in an ordered alternating-access cycle and translocates them together into the enterocyte cytoplasm. Glucose then exits across the basolateral membrane into the bloodstream via facilitated diffusion through GLUT2 (SLC2A2).
3. Coupled Osmotic and Cotransported Water Flux: Every 2 Na⁺ ions and 1 glucose molecule transported across SGLT1 (together with a paracellular Cl⁻ counter-ion) draw ~210 to 260 water molecules across the epithelium via osmotic gradients and direct cotransporter water channeling—capable of absorbing up to 1.0 to 1.5 liters of water per hour in an adult human small intestine, thereby outpacing ongoing cholera crypt secretion and rehydrating the vascular compartment orally.

After early empirical trials by Robert A. Phillips (1964) at NAMRU-2 in Taipei showed that glucose-electrolyte solutions caused net sodium and water absorption in cholera patients (though Phillips's hypertonic 400 mOsm/L formula caused osmotic diarrhea when miscalculated), two teams working independently at the Pakistan-SEATO Cholera Research Laboratory in Dhaka (now icddr,b) and the Johns Hopkins Center for Medical Research and Training in Kolkata achieved the definitive clinical breakthrough in 1968 (Norbert Hirschhorn et al., 1968; Pierce et al., 1968; Nalin et al., 1968):

• The Dhaka Trial (Nalin, Cash, Islam, Molla & Phillips, 1968, The Lancet): David R. Nalin and Richard A. Cash formulated an isotonic oral solution matched to the electrolyte composition of cholera stool containing an equimolar ~1:1 ratio of sodium to glucose and administered it via nasogastric tube or by mouth to adult cholera patients after initial shock resuscitation—reducing intravenous fluid needs by 79.6%.
• The 1971 Bangladesh Liberation War Field Proof (Mahalanabis et al., 1973): When war broke out in March 1971 and 10 million refugees fled into West Bengal (India), cholera swept through the overcrowded border camps at Bongaon, where intravenous saline supplies quickly ran out and the case-fatality rate reached 30%. Pediatrician Dilip Mahalanabis and his team mixed bulk packets of table salt, baking soda, potassium chloride, and glucose in drums of boiled water and trained mothers and family members to spoon-feed the solution continuously to dehydrated patients as soon as diarrhea began. Among 3,703 severely dehydrated cholera patients (including 1,200 children) treated at Bongaon almost exclusively with oral rehydration salts, only 135 died—a case-fatality rate of 3.6% (compared to 30% in neighboring camps relying on scarce IV bottles). That real-world demonstration convinced the World Health Organization (WHO) and UNICEF to launch the global Control of Diarrhoeal Diseases (CDD) program in 1978 (Mahalanabis et al., 1973; Fontaine et al., 2007).

Why must glucose concentration in ORS never exceed ~75–111 mmol/L (and why are commercial soft drinks, fruit juices, and sports drinks dangerous for severe dehydrating diarrhea)? If luminal glucose exceeds ~150–200 mmol/L (as in apple juice or cola, which have osmolarities of 550–750 mOsm/L and virtually no sodium, <5 mmol/L Na⁺), SGLT1 transporters saturate while the unabsorbed hyperosmolar sugar exerts an osmotic drag that pulls water out of the bloodstream into the gut lumen, worsening osmotic diarrhea and hypernatremia.

In 2002, following multicenter randomized controlled trials showing that lowering the total osmolarity of the original 1975 WHO formula from 311 mOsm/L (slightly hyperosmolar relative to human plasma at ~290 mOsm/L) down to 245 mOsm/L (hypo-osmolar) enhanced net water absorption along a favorable lumen-to-blood osmotic gradient, the WHO and UNICEF adopted Reduced-Osmolarity ORS, supplemented in 2004 with oral zinc (10–20 mg/day for 10–14 days) and resistant-starch / amylase-resistant polymer ORS (which releases glucose slowly inside the brush border without raising luminal osmolarity; Hahn et al., 2001; Binder et al., 2014):

1. Crane, R. K. (1960). Intestinal absorption of sugars. Physiological Reviews, 40(4), 789–825. https://doi.org/10.1152/physrev.1960.40.4.789
2. Schultz, S. G., & Zalusky, R. (1964). Ion transport in isolated rabbit ileum: II. The interaction between active sodium and active sugar transport. Journal of General Physiology, 47(6), 1043–1059. https://doi.org/10.1085/jgp.47.6.1043
3. Nalin, D. R., Cash, R. A., Islam, R., Molla, M., & Phillips, R. A. (1968). Oral maintenance therapy for cholera in adults. The Lancet, 292(7564), 370–373. https://doi.org/10.1016/S0140-6736(68)90591-690591-6)
4. Mahalanabis, D., Choudhuri, A. B., Bagchi, N. G., Bhattacharya, A. K., & Simpson, T. W. (1973). Oral fluid therapy of cholera among Bangladesh refugees. Johns Hopkins Medical Journal, 132(4), 197–205. https://pubmed.ncbi.nlm.nih.gov/4698667/
5. Editorial. (1978). Water with sugar and salt. The Lancet, 312(8084), 300–301. https://doi.org/10.1016/S0140-6736(78)91698-791698-7)
6. Hahn, S., Kim, Y., & Garner, P. (2001). Reduced osmolarity oral rehydration solution for treating dehydration due to diarrhoea in children: Systematic review. BMJ, 323(7304), 81–85. https://doi.org/10.1136/bmj.323.7304.81
7. Binder, H. J., Brown, I., Ramakrishna, B. S., & Young, G. P. (2014). Oral rehydration therapy in the second decade of the twenty-first century. Current Gastroenterology Reports, 16(3), 376. https://doi.org/10.1007/s11894-014-0376-2